Xifaxan success in Phase III TARGET-3 trial for IBS-Diarrhea.- Salix
Salix Pharmaceuticals, Ltd. announced the successful outcome of TARGET 3 � a Phase III randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeat treatment with Xifaxan ( rifaximin 550 mg TID ) (three times daily) for 14 days in subjects with Irritable Bowel Syndrome with Diarrhea, or IBS-D, who respond to an initial treatment course with rifaximin 550 mg TID for 14 days.
In the study a statistically significant greater proportion of rifaximin treated subjects (as compared to placebo) responded to repeat treatment as assessed by the composite primary endpoint of IBS-related abdominal pain and stool consistency during the 4 week treatment-free follow-up period (Primary Evaluation Period, or PEP) in the Double Blind Repeat Treatment Phase.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins